Study to Evaluate the Safety and Tolerability of CC-94676 in Participants With Metastatic Castration-Resistant Prostate Cancer

Completed · Phase 1

Conditions studied: Prostatic Neoplasms

In brief

The purpose of this study is to assess the safety, tolerability and preliminary efficacy of CC-94676 in men with progressive metastatic castration resistant prostate cancer.

Key facts

Study ID

NCT04428788

Run by

Celgene

People needed

131

Starts

2020-06-22

Expected to finish

2025-10-28

Last updated by the study team

2025-12-22

Who can join

Age: 18 and older. Sex: male. Healthy volunteers: not accepted.

You may qualify if…

• Must have histologically or cytologically confirmed adenocarcinoma of the prostate
• Progressed on androgen deprivation therapy (ADT) and at least one prior secondary hormonal therapy approved for castration-resistant prostate cancer (CRPC)
• Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

You may not qualify if…

• Prior treatment with an androgen receptor (AR) degrader
• Concurrent malignancy (present during screening) requiring treatment or history of prior malignancy active within 1 year prior to the first dose of IP
• Clinically significant venous thromboembolism within 3 months prior to the first dose of IP
• Any significant medical condition, such as uncontrolled infection, laboratory abnormality, or psychiatric illness
• Other protocol-defined inclusion/exclusion criteria apply

Where it is running

• Local Institution - 116 — Stanford, California, United States
• Local Institution - 122 — Washington D.C., District of Columbia, United States
• Local Institution - 103 — Sarasota, Florida, United States
• Local Institution - 121 — Thomasville, Georgia, United States
• Local Institution - 108 — Baltimore, Maryland, United States
• Local Institution - 104 — Boston, Massachusetts, United States
• Local Institution - 117 — Ann Arbor, Michigan, United States
• Local Institution - 102 — Grand Rapids, Michigan, United States
• Local Institution - 112 — New York, New York, United States
• Local Institution - 109 — New York, New York, United States
• Local Institution - 105 — New York, New York, United States
• Local Institution - 106 — Durham, North Carolina, United States
• Local Institution - 120 — Allentown, Pennsylvania, United States
• Local Institution - 113 — Philadelphia, Pennsylvania, United States
• Local Institution - 107 — Dallas, Texas, United States
• Local Institution - 119 — Houston, Texas, United States
• Local Institution - 101 — San Antonio, Texas, United States
• Local Institution - 115 — Seattle, Washington, United States
• Local Institution - 111 — Madison, Wisconsin, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.